Oxford Immunotec
Oxford Immunotec Schedules First Quarter 2015 Earnings Release and Conference Call for May 5, 2015
DGAP-News: Oxford Immunotec 2015-04-23 / 19:44 --------------------------------------------------------------------- OXFORD, United Kingdom and MARLBOROUGH, Mass., 2015-04-23 19:44 CEST (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) today announced that it plans to release first quarter 2015 financial results prior to market open on Tuesday, May 5, 2015. Dr. Peter Wrighton-Smith, Chief Executive Officer and Rick Altieri, Chief Financial Officer will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 35340282, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at http://www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT(R).TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test is the Company's second product and the first of three products we intend to launch for the transplantation market. Overall, the Company has six active development programs, each of which leverages our T cell and innate immune measuring technology. The Company is headquartered near Oxford, UK and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com. T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. CONTACTS: For Media Inquiries: Caroline Crawley Oxford Immunotec Tel: +44 1235 442796 ccrawley@oxfordimmunotec.com For Investor Inquiries: Rick Altieri Chief Financial Officer Oxford Immunotec Tel: +1 (508) 573-9953 raltieri@oxfordimmunotec.com Mark Klausner Westwicke Partners Tel: +1 (443) 213-0500 oxfordimmunotec@westwicke.com News Source: NASDAQ OMX --------------------------------------------------------------------- 2015-04-23 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oxford Immunotec United Kingdom ISIN: GB00BGFBB958 End of News DGAP News-Service --------------------------------------------------------------------- 348047 2015-04-23
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found